Aurinia Pharmaceuticals Inc. (AUPH)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 01:57PM EDT. Market open.
| Previous close | 5.17 |
| Open | 5.40 |
| Bid | 5.11 x 200 |
| Ask | 5.15 x 100 |
| Day's range | 5.10 - 5.55 |
| 52-week range | 4.71 - 12.43 |
| Volume | |
| Avg. volume | 2,119,929 |
| Market cap | 731.542M |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript May 2, 2024 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.07464, expectations were $-0.17. AUPH isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to the Aurinia […]
- Zacks
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Aurinia (AUPH) delivered earnings and revenue surprises of 82.35% and 8.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
When Will Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Breakeven?
With the business potentially at an important milestone, we thought we'd take a closer look at Aurinia Pharmaceuticals...
© 2024 Yahoo. All rights reserved.